BioSerenity
PrivateLast Round
Private Equity
Nov 13, 2023
Total Funding Raised
$120.95M
Company Overview
BioSerenity is a French medical technology company founded in 2014 that specializes in developing and deploying innovative wearable devices and digital health solutions for remote patient monitoring and diagnostics. The company's integrated platform combines smart clothing with medical sensors, a smartphone app, and a web platform that uses artificial intelligence (AI) to detect digital biomarkers. Initially focused on neurology and epilepsy, BioSerenity has expanded its solutions to include sleep disorders and cardiology. The company provides its services to hospitals and healthcare providers, aiming to improve patient care, streamline clinical workflows, and facilitate decentralized clinical trials. It has operations in Europe and the United States, with headquarters in Paris, France, and offices in the US. The company has received multiple rounds of funding to support its international expansion and the development of its AI-powered diagnostic tools.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Telemedicine, Medical AI, Health IoT, Clinical Trials
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioSerenity Comps
Public and private peers based on sector, stage, and business model.
BioSerenity Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Nov 13, 2023 | ||||
| Series B | Jun 18, 2019 | ||||
| Series A | Sep 20, 2017 | ||||
| Seed | Jun 8, 2015 |
Key People
Founding team and executive leadership
BioSerenity Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Idinvest Partners | Series A, Series B, Seed |
| Bpifrance | Series A, Series B |
| Dassault Systèmes | Series B |
| Jolt Capital | Private Equity |
| LBO France | Series B, Series A |
| Kurma Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Developing a premium home nursing service for VIP patients in Paris.
BioSerenity Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BioSerenity's valuation, stock price, and market status.
